Net proceeds from the transaction are expected to be used in accordance with Perrigo’s capital allocation priorities. Goldman Sachs is serving as financial advisor and A&O Shearman is serving as legal advisor for Perrigo. Jefferies LLC is serving as financial advisor and Sullivan and Cromwell LLP is serving as legal advisor to MeridianMade. About Perrigo Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the- counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. For more information, visit www.perrigo.com. About MeridianMade MeridianMade is a domestic, infant-focused nutrition platform dedicated to the development and manufacturing of high-quality infant formula. MeridianMade’s contract manufacturing services include spray drying, dry blending and packaging capabilities, supported by in-house R&D, clinical research, regulatory navigation and commercialization. For more information, visit https://meridianmade.us/. Forward-Looking Statements Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about the proposed divestiture of the Company’s Infant Formula business, including the timing and benefits thereof and the anticipated use of proceeds, our expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "forecast," "predict," "potential" or the negative of those terms or other comparable terminology. We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control, including our ability to complete the proposed divestment of the Infant Formula business, receipt of third-party approvals regarding the transaction, performance by counterparties to the transaction and the likelihood of satisfying the deferred payment milestones associated with the transaction, among others. These and other important factors, including those discussed in our Form 10-K for the year ended December 31, 2025 and in any subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Perrigo Contacts Eric Jacobson, Vice President, Global Investor Relations (616) 886-0375, eric.jacobson@perrigo.com Nick Gallagher, Associate Director, Global Investor Relations (269) 686-3238, nicholas.gallagher@perrigo.com MeridianMade Contact press@meridianmade.us